Assenagon Asset Management S.A. Increases Stock Holdings in Codexis, Inc. (NASDAQ:CDXS)

Assenagon Asset Management S.A. increased its position in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 23.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,103,442 shares of the biotechnology company's stock after buying an additional 209,207 shares during the quarter. Assenagon Asset Management S.A. owned 1.56% of Codexis worth $3,399,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Los Angeles Capital Management LLC bought a new position in Codexis during the 2nd quarter worth approximately $54,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Codexis in the first quarter worth $97,000. State Board of Administration of Florida Retirement System increased its stake in shares of Codexis by 57.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 28,500 shares of the biotechnology company's stock worth $99,000 after buying an additional 10,395 shares during the period. Marshall Wace LLP bought a new stake in Codexis during the 2nd quarter valued at $89,000. Finally, SG Americas Securities LLC boosted its position in Codexis by 72.6% during the 2nd quarter. SG Americas Securities LLC now owns 36,677 shares of the biotechnology company's stock valued at $114,000 after buying an additional 15,425 shares during the period. 78.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CDXS. Benchmark downgraded shares of Codexis from a "buy" rating to a "hold" rating in a research note on Monday, August 19th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $11.00 price target on shares of Codexis in a research report on Friday, September 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, Codexis has a consensus rating of "Hold" and an average target price of $8.75.

Codexis Trading Down 0.6 %

Shares of NASDAQ CDXS traded down $0.02 during midday trading on Thursday, hitting $3.19. 325,839 shares of the company traded hands, compared to its average volume of 523,701. Codexis, Inc. has a 12-month low of $1.51 and a 12-month high of $4.91. The firm has a market cap of $226.26 million, a P/E ratio of -2.97 and a beta of 2.08. The stock has a 50-day moving average price of $3.04 and a 200 day moving average price of $3.14. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.92 and a current ratio of 2.99.

Codexis (NASDAQ:CDXS - Get Free Report) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.06). Codexis had a negative return on equity of 64.06% and a negative net margin of 125.41%. The firm had revenue of $7.98 million during the quarter, compared to the consensus estimate of $7.64 million. During the same period in the prior year, the company posted ($0.17) EPS. As a group, analysts expect that Codexis, Inc. will post -0.75 earnings per share for the current year.

Insider Buying and Selling

In other Codexis news, major shareholder Opaleye Management Inc. bought 61,000 shares of the stock in a transaction dated Wednesday, September 18th. The stock was purchased at an average cost of $3.16 per share, for a total transaction of $192,760.00. Following the completion of the acquisition, the insider now owns 7,380,000 shares of the company's stock, valued at approximately $23,320,800. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders acquired a total of 1,166,000 shares of company stock worth $3,514,910 in the last three months. 2.10% of the stock is owned by corporate insiders.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.